default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

CJ HealthCare’s new gastric acid blocker K-Cab sold ₩ 1.5 billion in March

Jeong Sae-im  Published 2019.04.18  15:27  Updated 2019.04.18 15:27

공유
default_news_ad2

CJ HealthCare’s K-Cab Tab., the nation’s 30th novel drug, recorded 1.53 billion won ($1.34 million) outpatient prescription sales in a single month after the market release, raising the expectations of becoming a blockbuster drug.

CJ HealthCare’s K-Cab, a treatment for the gastroesophageal reflux disease

According to UBIST data, K-Cab (ingredient: tegoprazan), a treatment for the gastroesophageal reflux disease, sold 1.53 billion won in March.

Seoul National University Hospital first started prescribing K-Cab. The Severance Hospital and Samsung Medical Center are likely to follow suit as the medicine recently passed the hospitals’ drug review committee.

As a potassium-competitive acid blocker (P-CAB), K-Cab overcame the shortcoming of conventional therapies such as proton pump inhibitors (PPI). The medicine obtained approval last year and arrived in the market with insurance benefit on March 1. The price is 1,300 won ($1.14) per tablet.

CJ HealthCare is seeking to expand K-Cab’s indication into treat stomach ulcer and eradicate Helicobacter pylori in the stomach.

An expanded indication could give K-Cab a chance to replace widely-used PPI-class drugs.

same@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch